Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515728 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL15977917 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL7914906 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL25206528 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL198354 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23234144 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL18970877 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23016820 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL61278 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL31314689 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713448-A1 | METHOD FOR TREATMENT OF A BIOLOGICAL SAMPLE | QIAGEN GmbH (DE) | 2026-03-25 | — | — | EP | claimed |
| CN-120082629-A | Reagent for detecting creatine kinase, kit and application | 湖南师范大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119303213-A | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2024235998-A1 | METHOD FOR TREATMENT OF A BIOLOGICAL SAMPLE | QIAGEN GMBH (DE) | 2024-11-21 | — | — | WO | claimed |
| CN-113727750-B | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118555975-A | Method for treating airway stenosis or narrowing | 艾里弗医疗公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118454075-A | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2024-08-09 | — | — | CN | claimed |
| CN-118382704-A | Method for reducing measurement error caused by haemoglobin | 东洋纺株式会社 | 2024-07-23 | — | — | CN | claimed |
| CN-111051883-B | Treatment liquid for use in clathrating cyclodextrin-containing steroid | 富士瑞必欧株式会社 | 2024-04-19 | — | — | CN | claimed |
| EP-3712614-B1 | TREATMENT LIQUID FOR USE IN DESORPTION OF STEROID INCLUDED IN CYCLODEXTRIN | FUJIREBIO KK (JP) | 2024-03-06 | — | — | EP | claimed |
| WO-2010037109-A2 | PROCESS FOR ACCELERATED CAPTURE OF CARBON DIOXIDE | AKERMIN, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| EP-1710320-B1 | A METHOD FOR DETERMINATION OF DNA FRAGMENTATION IN ANIMAL SPERM CELL | UNIV MADRID AUTONOMA (ES) | 2010-01-06 | — | — | EP | claimed |
| US-20070281298-A1 | Procedure for the Determination of Fragmentation of Dna in Animal Sperm | GOSALVEZ BERENGUER JAIME | 2007-12-06 | — | — | US | claimed |
| EP-1710320-A1 | A METHOD FOR DETERMINATION OF DNA FRAGMENTATION IN ANIMAL SPERM CELL | Universidad Autónoma de Madrid (ES) | 2006-10-11 | — | — | EP | claimed |
| US-6692537-B1 | ENZYME OF 2-ELECTRON OXIDOREDUCTASE TYPE IN THE PRESENCE OF AT LEAST ONE DONOR FOR THE SAID ENZYME AND AT LEAST ONE NONIONIC FATTY SUCRONAMIDE | L'OREAL S.A. (FR) | 2004-02-17 | — | — | US | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
| US-6509393-B2 | Phase change inks | XEROX CORPORATION | 2003-01-21 | — | — | US | claimed |
| US-20020137816-A1 | Phase change inks | XEROX CORPORATION | 2002-09-26 | — | — | US | claimed |
| US-6372030-B1 | INK VEHICLE SELECTED FROM 4-(HEXADECYLAMINO)BENZYLAMINE, N-OCTANOYL-N-METHYL GLUCAMINE, OCTANOIC HYDRAZIDE, 4-HEXADECYL SULFONYL ANILINE, A CONDUCTIVE COMPLEX OF AN AMINE COMPOUND WITH A PHOSPHORUS OR SULFUR-CONTAINING ACID | XEROX CORPORATION | 2002-04-16 | — | — | US | claimed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | EPHX2 3458/4885MEN1 3705/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.